期刊文献+

坎格列净纳米晶体冻干粉的制备及其药动学和药效学评价

Preparation of canagliflozin nanocrystals lyophilized powder and evaluation of its pharmacokinetics and pharmacodynamics
下载PDF
导出
摘要 目的制备坎格列净纳米晶体(CFZ-NCs),并考察其在大鼠体内的药动学以及控制血糖的效果。方法以维生素E聚乙二醇1000琥珀酸酯(TPGS)和十二烷基硫酸钠(SDS)作为稳定剂,采用高压均质法制备CFZ-NCs,并通过冷冻干燥工艺将其固化成固体粉末;分别考察了CFZ-NCs及其冻干粉的粒径分布、Zeta电位;并在扫描电镜下观察CFZ-NCs的微观结构;比较坎格列净(CFZ)混悬剂及其纳米晶体的体外药物溶出速率;评价CFZ混悬剂和CFZ-NCs经大鼠口服给药后的体内药动学以及对糖尿病大鼠血糖水平的控制效果。结果CFZ-NCs及其冻干粉复溶后的粒径分布分别为(281.7±15.5)、(297.7±13.9)nm,Zeta电位分别为(-36.1±1.0)、(-36.9±0.7)mV,在扫描电镜下可观察到CFZ-NCs呈不规则块状分布;CFZ-NCs冻干粉的体外溶出速率显著高于CFZ混悬剂;大鼠口服CFZ-NCs冻干粉后,其药物达峰质量浓度和口服生物利用度显著高于CFZ混悬剂,对血糖控制水平效果也明显优于CFZ混悬剂。结论将CFZ制备成CFZ-NCs冻干粉,能显著提高药物的口服生物利用度,达到良好的控制血糖效果,对CFZ的二次开发奠定实验基础。 Objective To prepare canagliflozin nanocrystals(CFZ-NCs)and investigate their pharmacokinetics in rats and blood glucose control effects in diabetic rats.Methods By using vitamin E polyethylene glycol 1000 succinate(TPGS)and sodium lauryl sulfate(SDS)as stabilizers,CFZ-NCs were prepared by a high-pressure homogenization method,and solidified CFZ-NCs into solid powder by freeze-drying process.The particle size distribution and Zeta potential of CFZ-NCs and their lyophilized powders were investigated,respectively.The microstructure of CFZ-NCs was observed under scanning electron microscope(SEM).The in vitro dissolution rates of canagliflozin(CFZ)suspensions and CFZ-NCs were compared.The in vivo pharmacokinetics of CFZ suspensions and CFZ-NCs after oral administration in rats and the control effect on blood glucose levels in diabetic rats were evaluated.Results The particle size distributions of CFZ-NCs and CFZ-NCs lyophilized powder after reconstitution were(281.7±15.5)and(297.7±13.9)nm,and the Zeta potentials were(-36.1±1.0)and(-36.9±0.7)mV,respectively.The CFZ-NCs were irregularly distributed under SEM.The in vitro dissolution rate of CFZ-NCs lyophilized powder was significantly higher than that of CFZ suspensions.After oral administration of CFZ-NCs lyophilized powder in rats,the peak plasma concentration and oral bioavailability were significantly higher than CFZ suspensions,and the effect on blood glucose control level was significantly better than CFZ suspensions.Conclusion CFZ was prepared into CFZ-NCs lyophilized powder,which could significantly improve the oral bioavai-lability and achieve a good blood glucose control effect.It was of great significance for the secondary development of CFZ.
作者 刘佳 吉莉 陈洁 黄雅菲 LIU Jia;JI Li;CHEN Jie;HUANG Yafei(Department of Pharmacy,the People′s Hospital of Lishui District of Nanjing,Nanjing 211200,China)
出处 《西北药学杂志》 CAS 2021年第6期952-956,共5页 Northwest Pharmaceutical Journal
基金 2020年度江苏省药学会-天晴医院药学基金科研课题(编号:Q202054)。
关键词 坎格列净 纳米晶体 高压均质法 溶出速率 生物利用度 血糖水平 canagliflozin nanocrystals high pressure homogenization method dissolution rate bioavailability blood glucose level
  • 相关文献

参考文献6

二级参考文献41

  • 1Bo yle JP,Thompson TJ,Gregg EW,et al.Projection of the year 2050 burden of diabetes in the US adult population:Dynamic mo deling of incidence,mortality,and prediabetes prevalence[J].Popul Health Metr,2010,8:29.
  • 2Garber AJ,Abrahamson MJ,Barzilay JI,et al.AACE Comprehensive diabetes management algorithm[J].Endocr Pract,2013,19(2):327-336.
  • 3Neumiller JJ,White JR Jr,Campbell RK.Sodium-glucose co-transport inhibitors:Progress and therapeutic potential in type 2 diabetes mellitus[J].Drugs,2010,70:377-385.
  • 4Kim Y,Babu AR.Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes[J].Diabetes Metab Syndr Obes,2012,5:313-327.
  • 5Idris I,Donnelly R.Sodium-glucoseco transporter-2inhibitors:An emerging new class of oral antidiabetic drug[J].Diabetes Obes Metab,2009,11(2):79-88.
  • 6Cada DJ,Kyle T,Dennis J,et al.Canagliflozin[J].Hosp Pharm,2013,48(10):855-867.
  • 7Polidori D,Sha S,Ghosh A,et al.Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2013,98(5):E867-E871.
  • 8Nomura S,Sakamaki S,Hongu M,et al.Discovery of canagliflozin,a novel c-glucoside with thiophene ring,as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus[J].J Med Chem,2010,53(17):6355-6360.
  • 9Stenlof K,Cefalu WT,Kim KA,et al.Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise[J].Diabetes Obes Metab,2013,15(4):378-382.
  • 10Schernthaner G,Gross JL,Rosenstock J,et al.Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea[J].Diabetes Care,2013,36(19):2508-2515.

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部